Loss of Androgen Receptor Expression Promotes a Stem-Like Cell Phenotype in Prostate Cancer through STAT3 Signaling

Anne Schroeder,1,+ Andreas Herrmann,2,+ Gregory Cherryholmes,2 Claudia Kowolik,1 Ralf Buettner,1 Sumanta Pal,3 Hua Yu,2 Gerhard Müller-Newen,4,* and Richard Jove1,*

1Department of Molecular Medicine
2Department of Cancer Immunotherapy and Tumor Immunology
3Department of Medical Oncology
Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
4Institute for Biochemistry, Universitätsklinikum RWTH Aachen, 52074 Aachen, Germany
+Contributed equally
*Correspondence: rjove@coh.org and mueller-newen@rwth-aachen.de

Running Title: IL-6/STAT3 Signaling Enhances Prostate Cancer Stem-Like Cells

Keywords: STAT3, IL-6, Prostate Cancer, Cancer stem-like cell, AR

Notes: The authors declare that they have no conflict of interest.

Words: 4973, 5 Figures, 3 Supplementary Figures
ABSTRACT

Androgen receptor (AR) signaling is important for prostate cancer progression. However, androgen-deprivation and/or AR targeting-based therapies often lead to resistance. Here we demonstrate that loss of AR expression results in STAT3 activation in prostate cancer cells. AR downregulation further leads to development of prostate cancer stem-like cells (CSC), which requires STAT3. In human prostate tumor tissues, elevated cancer stem-like cell markers coincide with those cells exhibiting high STAT3 activity and low AR expression. AR downregulation-induced STAT3 activation is mediated through increased IL-6 expression. Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor cells significantly reduced prostate tumor growth and CSCs. Together, these findings indicate an opposing role of AR and STAT3 in prostate CSC development.
INTRODUCTION

Prostate cancer (PC) is the most common cause of male cancer-related deaths in Western countries. Current treatment relies on targeting androgen receptor (AR) signaling by hormone deprivation or anti-androgen therapy. However, tumors are heterogeneous and hormone depletion often results in the selection of drug resistant, highly metastatic tumor cells that survive targeted therapy. Hence, the initial response to treatment is often followed by tumor recurrence (1, 2). The development of recurring PC is not well understood and remains a challenge for more effective therapeutic intervention. Even with new therapies including abiraterone and enzalutamide targeting AR signaling, some cancers do not respond and ultimately recur. One suggested model to explain recurrence proposes the selection of cancer stem-like cells (CSC) that survive drug therapy. Because selected CSCs are thought to be resistant to conventional therapy, and have been suggested to resupply the highly proliferative tumor cell population, failure to eliminate this cell population might result in tumor relapse (3). Cancer cells with stem-cell like properties share phenotypic features with somatic stem cells and are characterized by self-renewal and multilineage differentiation (4). Importantly, the development of CSCs is not well understood and identification of signaling pathways that regulate phenotypic and tumorigenic potential of CSCs might provide new insights for drug development to prevent tumor drug resistance and relapse (5).

Signal Transducer and Activator of Transcription 3 (STAT3) protein has been implicated in maintaining pluripotency and self-renewing processes in embryonic stem cells and glioblastoma stem cells (6-8). STAT3 is a member of the STAT family of transcription factors that transduce signals from cytokine and growth factor receptors on the cell surface and regulate gene
expression responses in the nucleus (9). In particular, STAT3 regulates the expression of genes that control cell proliferation, survival and immune responses (10). Persistent activation of STAT3 signaling is oncogenic and has been demonstrated in a wide variety of human tumor specimens and tumor cell lines including leukemias, lymphomas, and a variety of solid tumors such as head and neck cancer, colon, breast and prostate cancer (11-14). Activated STAT3 signaling contributes to oncogenesis by inducing cell proliferation, preventing apoptosis, and suppressing anti-tumor immune responses (15-20). Moreover, constitutive activation of STAT3 has been shown to be important in tumor metastasis and angiogenesis (21-23).

Besides growth factor receptors and non-receptor tyrosine kinases, including EGFR, PDGFR and SRC, activation of STAT3 is mediated by cytokine receptors such as interleukin-6 (IL-6) receptor (9, 24). IL-6 signal transduction is initiated by ligand binding to the IL-6Ra/gp130 receptor complex followed by activation of an intracellular signaling cascade in which receptor-associated Janus Kinases (JAKs) phosphorylate STAT3 on a single tyrosine residue. Upon STAT3 phosphorylation at Y705, STAT3 forms stable dimers and translocates to the nucleus, where it binds to its specific promoter sequences to induce target gene expression (9, 24).

The IL-6/STAT3 signaling pathway has been implicated in the progression of prostate tumors (25). Clinical studies demonstrated elevated levels of IL-6 in blood plasma and blood serum of patients with hormone-refractory prostate cancer (HRPC) or metastatic prostate cancer, compared to benign or non-malignant forms (26, 27). Thus, high IL-6 expression (> 7 pg/ml) has been suggested to participate in malignant progression from hormone-sensitive to hormone-refractory prostate cancer (28). Moreover, IL-6 has been implicated in the maintenance of stem-
like cancer cells. In gene expression profiles of CD44\(^+\)/CD24\(-\) breast CSCs, IL-6 has been demonstrated to be upregulated (29). Genetic signatures of prostate CSCs revealed activation of JAK/STAT3 signal transduction in this cell population (30). These observations highlight the IL-6/gp130/STAT3 signaling pathway as a potential target for prostate cancer and PC stem-like cells (31). The IL-6 receptor fusion protein (IL-6\(^{\text{RFP}}\)) has been described as a cytokine “trap” that efficiently sequesters soluble IL-6 and thereby prevents activation of downstream IL-6 signaling (32-34).

Based on these observations, we investigated the role of activated STAT3 signaling upon androgen blockade on CSC development in PC. Our findings provide new mechanistic insights for PC tumor relapse and CSC development involving STAT3 signaling. We further propose the IL-6 receptor fusion protein (IL-6\(^{\text{RFP}}\)) as a potential approach to inhibit IL-6/STAT3 signaling and overcome recurrent prostate cancer.
MATERIALS AND METHODS

Cells. Murine epithelial prostate cancer cells TRAMP-C1 (TC1) were obtained originally from American Type Culture Collection (ATCC). TC1- control-, STAT3-, or AR-shRNA engineered cell lines were generated by transducing lentiviral particles containing pLKO1-STAT3 mouse shRNAs (TRCN0000071456), (TRCN0000071453), and (TRCN0000071455) or pLKO1-AR mouse shRNAs (TRCN0000026189), (TRCN0000026195), and (TRCN0000026211) (SIGMA). Pooled populations of transduced cells were used to avoid selection for clonal variants. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) medium supplemented with 5% FBS (Gibco, Rockville, MD), 5% Nu-Serum IV, 0.005 mg/ml bovine insulin, 10 nM dehydroisoandrosterone (SIGMA) and 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco, Rockville, MD). DU145 cells expressing pLKO1-human STAT3 shRNA (TRCN0000020840) or pLKO1-non-silencing control shRNA were maintained in RPMI supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 µg/ml puromycin. Hek293 cells were maintained in DMEM medium supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin. HEK<sup>IL-6<sup>RFP</sup></sup> cells were stably reconstituted with a cDNA encoding murine IL-6<sup>RFP</sup> in pcDNA5 FRT/TO using the Flp-In technique (Invitrogen) and selected with Hygromycin (1:100). All cells were obtained before 2008.

In vivo experiments. The Il2-rg(ko)/NOD-SCID mice were kindly provided by Dr. Jun Wu (City of Hope, Duarte, CA). Rag1(ko)Momj/B6.129S7 mice were purchased from Jackson Laboratory. Mouse care and experimental procedures were performed under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Institutional Animal Care and Use Committee of Beckman Research Institute at City of Hope.
National Medical Center. Approximately 2-2.5 x 10^6 TC1, TC1 cells expressing non-silencing control-, STAT3-, or AR-shRNA were implanted in mice subcutaneously with HBSS. Palpable tumors were treated peritumorally with either vehicle control (10% EtOH, 90% corn oil), 100 µl flutamide [25 mg/kg] or bicalutamide [50 mg/kg] every other day. 200 µl vehicle control (CM of parental HEK cells) or IL-6RFP [1.8 µg/kg] were injected twice daily. Mice were sacrificed 3-4 weeks after tumor challenge, tumor specimens were harvested and prepared 2 h after last drug treatment for necroptic analysis.

**Immunofluorescence.** For immunofluorescence staining of frozen Matrigel plugs, tissue sections were fixed with 2% paraformaldehyde, permeabilized in methanol, and blocked in PBS supplemented with 10% goat serum and 2.5% mouse serum (Sigma). Sections were incubated overnight with primary antibodies (pYSTAT3, Santa Cruz Biotechnology), AR, Nanog, CD44 (Epitmoics), CD31 (BD-Bioscience), cleaved Caspase3, His (Cell Signaling), Ki67, MSI-1, CD44, Sox-2 (Abcam) diluted 1:50 – 1:100 in PBS containing 10% goat and 2.5% mouse sera. The next day sections were washed with PBS thrice and incubated for 1 h with fluorophore-conjugated secondary antibodies and Hoechst33342 (Invitrogen). Immunofluorescence stainings were analyzed by confocal microscopy (LSM510Meta, Zeiss, Jena, Germany). To acquire mean fluorescence intensities (MFIs), single fluorescence intensities of fluorophore-conjugated secondary antibodies in regions of interest were recorded by total fluorescence per field of view in a 12 bit mode and relative units were quantified and averaged.

Archival human prostate carcinoma tissues from an anonymous group of patients were provided by the Pathology Core of City of Hope Comprehensive Cancer Center. Tumor tissues were
formalin fixed and paraffin embedded. Sections of 3 μm were deparaffinized, and processed as described above. These sections were stained with antibodies raised against pYSTAT3 (1:50 Santa Cruz Biotechnology), AR (1:50 Epitomics), MSI-1 (1:50 Ebioscience), Sox2, Nanog, CD44, integrin α2β1 (1:50 Abcam), and secondary antibodies conjugated to fluorophores diluted 1:100 (Invitrogen), additionally incubated with Hoechst33342 (Invitrogen), then mounted with Mowiol and analyzed by confocal microscopy.

**Intravital multiphoton microscopy (IVMPM).** Mice were anesthetized with an isoflurane/oxygen gas, and prepared for surgery. Then mice were injected with 100 µg dextran-rhodamine and 25 µg of Hoechst33342 (Invitrogen) intravenously. Tumor bearing mice continued to receive isofluorane/oxygen anesthesia while 2-photon live imaging was performed using Prairie Technologies Ultima microscope (Middleton, WI). To record rhodamine, signals were measured at λ[excit] = 860 nm with emission between 565 nm – 615 nm (rhodamine). For recording Hoechst33342, emission signals were recorded at λ[excit] = 730 nm with emission between 435 nm – 485 nm. Extracellular matrix (ECM) emission was given by second harmonic generation at λ[excit] = 890 nm (Coherent Chameleon Ultra II Ti:Sa laser). Images were acquired using an Ultima Multiphoton Microscopy System (Prairie Technologies) equipped with Prairie View software and non-descanned Hamamatsu PhotoMultiplier Tubes. Images were collected in 512x512 pixels, 16-bit resolution. TIFF formatted images were analyzed by Image Pro Plus professional imaging software (Media Cybernetics, Bethesda, MD).

**Western blot analysis.** Cell lysates were prepared and protein concentrations were determined by Bio-Rad protein assay. Equivalent amounts of total proteins were separated by 10% SDS-
PAGE (Invitrogen), subjected to immunoblotting, probed with the respective antibodies, and detected for signals using horseradish peroxidase–conjugated secondary antibodies by enhanced chemiluminescence (Amersham).

**Tumor sphere formation.** Cells were resuspended and dissociated into single cells by using a 40 µm cell strainer. To remove remaining serum, cells were washed thrice with HBSS (Invitrogen). Then, tumor cells were resuspended in 3 ml TSM consisting of DMEM F-12, L-Glutamine (1%), 1M Heps (2.5%), B-27 (50X), Heparin Sodium, and plated at a density of 4 x 10^4 cells/6-well plate. 20 ng/ml FGF-2 and EGF were added freshly. Tumor spheres with at least 20 cells per sphere were counted every other day using a transmitted light microscope for six days.
RESULTS

Loss of AR expression activates STAT3 signaling in prostate cancer cells

Treatment with anti-androgens is one of the standard therapies for androgen-sensitive prostate cancer. Development of androgen-insensitivity is the major obstacle for therapeutic intervention in recurrent prostate cancer. To determine the role of STAT3 in the transition from androgen-sensitive to hormone-refractory prostate cancer upon hormone deprivation, mice bearing TC1 murine prostate tumors derived from TRAMP transgenic mice were treated with the AR antagonist flutamide. TC1 cells implanted s.c. into Rag1−/− mice, established tumors within four weeks after implantation and expressed AR. Treatment with flutamide resulted in an immediate growth suppression (fig. 1A, F1). However, repeated flutamide administration did not result in tumor rejection, but rather continued tumor growth (fig. 1A, FII). Compared to vehicle treated control, AR expression was significantly decreased at the onset of flutamide administration (fig. 1B, F1; fig. 1C, F1) as well as in advanced tumor growth (fig. 1B, FII; fig. 1C, FII). By contrast, STAT3 expression and activation significantly increased in TC1 tumors challenged with flutamide, as shown by Western blot analysis and immunofluorescence staining (fig. 1B, F1, FII; fig. 1C, F1, FII).

Using RNAi approaches to silence either AR or STAT3 expression in prostate cancer cells, tumor growth kinetics of engrafted engineered cells indicate that STAT3 knockdown delays tumor growth significantly (fig. 1D). Conversely, silencing AR expression had no effect on tumor growth (fig. 1D), tumor vasculature (fig. S1A), or proliferative activity (fig. S1B). Furthermore, AR knockdown resulted in a more robust STAT3 activation, suggesting that STAT3 signaling compensates for silenced AR and promotes tumor growth (fig. 1E). In all
RNAi experiments, pooled populations of transduced cells were used to avoid selection of clonal variants and RNAi specificity was validated. Hence, downregulation of AR signaling achieved either by antagonizing AR with flutamide or silencing AR expression through RNAi is accompanied by enhanced STAT3 activity, thereby favoring disease progression and tumor growth. Correspondingly, AR mRNA expression is significantly decreased in association with enhanced STAT3 activity in TC2 murine prostate cancer cells (fig. S1C). TC2 cells are considered to represent more advanced prostate cancer than TC1 cells, which is reflected by significantly improved tumor growth (fig. S1D) and elevated expression of Ras and Myc similar to high-grade human prostate cancer (fig. S1E).

**AR downregulation-associated STAT3 activation promotes the development of prostate CSCs**

Because enhanced STAT3 activity in cancer cells has been suggested to impact the tumorigenic potential by unbalancing differentiation and promoting the expansion of cancer stem-like cells, we analyzed the potential of STAT3 and AR to induce a CSC phenotype. Antagonizing AR in murine prostate tumors with flutamide resulted in significantly elevated protein expression of Musashi-1, Sox2, and CD44 (fig. 2A). Furthermore, AR silencing promoted tumor sphere formation of prostate cancer cells (fig. 2B, left panel), associated with increased STAT3 activity as well as increased expression of Musashi-1 and Sox2 (fig. 2B, right panel). Thus, AR inhibition selected for a shift from AR+/pSTAT3−/MSI−/Sox2− expression to a cancer cell stem-like phenotype with AR−/pSTAT3+/MSI+/Sox2+ expression as seen both *in vitro* and *in vivo* (fig. 2C). In striking contrast, genetic silencing of STAT3 suppressed tumor sphere formation significantly, concomitant with reduction of CSC marker expression (fig. 2B and C). This
indicates that AR signaling downregulation, achieved by either androgen antagonists or genetic silencing, favors STAT3 activity and consequently expression of CSC markers leading to the induction of a prostate CSC phenotype. As shown in figure 2D, AR is not associated with CD44 expression (upper panel), while pSTAT3+/CD44+ expressing cells represent the major population (lower panel) in untreated prostate tumors. Hence, reduced AR activity promotes the CSC phenotype at least in part through activation of STAT3.

**Human prostate CSCs are characterized by low AR and high p-STAT3 levels**

To elucidate the role of STAT3 activity in mounting the CSC repertoire resulting in sustained malignancy of human prostate tumors, we investigated the co-expression of STAT3 and AR with CD44, which is thought to impact tumor initiation as well as homing/metastasis to the bone marrow, and Sox2 and integrin α2β1, both of which are involved in self-renewal. As shown by analysis of patient biopsies, activated STAT3 is associated predominantly with elevated Sox2 and integrin α2β1 expression (fig. 3A), as well as with CD44, Musashi-1, and Nanog expression (fig. S2AB). In contrast, lack of pSTAT3 is associated with substantially decreased expression of Sox2 and integrin α2β1. Notably, pSTAT3 does not coincide with AR expression (fig. 3B). Accordingly, CD44 or Sox2 protein expression is not accompanied by AR expression, which is instead expressed locally constrained and excluded from CD44+ or Sox2+ cell clusters (fig. 3C). Thus, Sox2+ human CSCs of the prostate characteristically express elevated pSTAT3 but not AR (fig. 3D, fig. S2B), which emphasizes a critical role for STAT3 in tumor progression.
Blocking IL-6/STAT3 signaling inhibits development of prostate CSCs

Since IL-6 mRNA expression was elevated in AR-targeted tumors by either anti-androgen or silencing of AR (fig. 4A), we evaluated the role of IL-6 as a potential mediator of STAT3 activation in prostate CSCs. We employed the IL-6 cytokine “trap” IL-6RFP, a soluble fusion protein of the ligand-binding domains of the IL-6 receptor subunits gp130 and IL-6Rα (32). In vitro characterization of IL-6RFP verified IL-6 binding capability and IL-6 neutralizing activity in prostate cancer cells (fig. S3A-G). Although systemic in vivo delivery of IL-6RFP induces a significant delay in tumor growth kinetics, local administration of IL-6RFP shows an improved anti-tumoral efficacy early on (fig. S3H). Most importantly, comparison of mice treated with equimolar concentrations of IL-6RFP or anti-IL-6 antibodies revealed that antitumoral efficacy of IL-6RFP is improved by 3-fold over anti-IL-6 antibodies (fig. 4B and S3I). Moreover, compared to anti-IL-6 cytokine depletion antibodies, IL-6RFP driven inhibition of STAT3 signaling is considerably enhanced (3.5 fold) (fig. S3G).

In murine 3D cell culture in vitro, we evaluated the maturation of CD44+/Sox2+ tumor spheres upon IL-6RFP treatment, which resulted in decreased sphere formation and STAT3 activity (fig. S3J). Therefore, we assessed the therapeutic efficacy of blocking IL-6 signaling by administering IL-6RFP in vivo and targeting the “stemness” phenotype in prostate cancer. Treatment with IL-6RFP resulted in significantly reduced STAT3 activity, concomitant with decreased protein expression levels of MSI-1, Sox2, CD44, and Nanog (fig. 4CDE, fig. S3JK).

As shown by immunofluorescence staining of tumor microsections, the phosphorylation of STAT3 (fig. 4D) and expression of stem cell markers, such as MSI-1 and Nanog (fig. 4E, fig. S3K), is locally inhibited by tumor permeating IL-6RFP. This finding indicates that blocking IL-6
mediated STAT3 signaling prevents maturation of multipotent CSC populations by inhibiting the expression of critical “stemness” regulators. Moreover, the regenerative potential of human prostate CSCs was considerably reduced after blocking IL-6/STAT3 signaling by IL-6RFP. Human tumor sphere formation was significantly inhibited, accompanied by diminished expression of pSTAT3, MSI-1, and Sox2 (fig. 4F). As anticipated from rodent prostate cancer stem-like cell populations, the presence of STAT3 is essential to mediate the expression of human CSC markers such as MSI-1 and Sox2, as well as triggering tumor sphere formation as shown by STAT3 knockdown assays (fig. 4G). We confirmed these findings by treating human DU145 tumors with IL-6RFP resulting in significant tumor growth delay (fig. 4H). Tumor permeating IL-6RFP efficiently inhibited STAT3 activation (fig. 4I) and led to dramatically reduced expression of Sox2 and MSI-1 as shown by Western blot analysis from tumor homogenates (fig. 4K). Thus, blocking IL-6/STAT3 signaling substantially diminishes the CSC phenotype in the prostate.

**Targeting both IL-6/STAT3 and AR signaling pathways gives stronger anti-tumor effects**

Both therapeutic interventions, androgen depletion and inhibition of IL-6 triggered STAT3 signaling, exert anti-tumor activity as monotherapy. Furthermore, silencing IL-6/STAT3 signaling prevents prostate CSC maturation. Therefore we combined the clinically more relevant anti-androgen, bicalutamide, and IL-6RFP treatments to assess their combined potential for therapeutic benefit. Combinatorial therapy significantly reduced tumor growth but showed only slightly improved anti-tumor efficiency compared to treatment with IL-6RFP alone, while anti-androgen administration alone had a minor effect on tumor growth kinetics (fig. 5A) Tumors treated with IL-6RFP alone or in combination with bicalutamide were positive for apoptotic cell
death associated with downregulation of Bcl-2 and BclXL (fig. 5B), and exhibited a significant
decrease in proliferative activity as shown by Ki67\(^+\) staining (fig. 5C). Interestingly, androgen-
depletion alone led to accumulation of a CD44\(^+\) cell population in the tumor, as shown by 2-
photon imaging *in vivo* (fig. 5D). This indicates that bicalutamide treatment contributes to
undesired CD44 expression suggestive of CSC development in prostate tumor tissue. By
contrast, combination with IL-6\(^\text{RFP}\) or IL-6\(^\text{RFP}\) treatment alone resulted in significantly decreased
amounts of CD44\(^+\) cells (fig. 5D). Importantly, while bicalutamide administration alone had no
beneficial effect on CSC marker expression, combined androgen depletion and IL-6\(^\text{RFP}\) treatment
enhanced suppression of MSI-1 and Sox2 expression (fig. 5E).
DISCUSSION

Standard treatment for prostate cancer targets the AR signaling pathway. However, therapeutic intervention often results in tumor relapse due to drug resistance and mechanistic explanations for this failure are diverse. A model based on the presence of prostate CSCs that are selected for drug resistance and allow sustained tumor progression could provide an explanation (35). Nevertheless, the underlying mechanisms for development of CSCs are not well understood. The cell populations initiating tumor growth and driving tumor relapse as a consequence of conventional therapies remain undefined. It has been suggested that CSCs may derive from somatic stem cells, progenitor or differentiated cells as well as highly proliferative, differentiated cancer cells by genetic or tumor microenvironment alterations (4). In these models, CSCs have been proposed to induce tumor growth and differentiate into the various cell types within a tumor. For the identification of CSCs, several markers have been suggested including Sox2, Nanog, CD44, integrin α2β1, and MSI-1 (36-38).

Here, we mainly use murine tumor cells derived from transgenic spontaneous adenocarcinoma of the mouse prostate (TRAMP) model, which are of luminal origin, mirror primary PC (39) and express AR and STAT3. We demonstrate that chemotherapeutic intervention targeting the AR signaling pathway, which is important for differentiation and survival, promotes the development of a CSC phenotype and that this may, at least in part, be responsible for tumor relapse. Our data further indicate that inhibition of AR by either anti-androgens or gene-silencing results in up-regulation of the IL-6 cytokine (fig. 4A). While anti-androgen slows tumor growth more effectively than AR knockdown, this may reflect a delay in elevated IL-6 induction by anti-androgen treatment. Importantly, IL-6 induced activation of STAT3 signal transduction
coincides with augmented CSC marker expression. We show that lack of AR is associated with this elevated STAT3 activity and augmented expression of CSC markers. In particular, AR-negative tumor cells exhibited increased MSI-1, Sox2 and CD44 expression, which was associated with activated STAT3 signaling. In human prostate cancer tissues, elevated CSC markers coincided with those cells exhibiting high STAT3 activity and low AR expression, indicating an inverse correlation between AR and pSTAT3 expression in the maturation of CSC in human prostate cancer progression. This counter-regulation of the AR and STAT3 signaling pathways in both mouse and human tumor cells provides a potential explanation for failure of mono-therapies inhibiting the AR signaling pathway.

To effectively target the maturation of CSCs in prostate cancer, we applied a chimeric soluble IL-6 receptor fusion protein (IL-6\textsuperscript{RFP}) with improved inhibitory activity compared to IL-6 depletion antibodies. Inhibition of the STAT3 signaling pathway by gene silencing or using IL-6\textsuperscript{RFP} in murine and human prostate cancer cells resulted in decreased CSC phenotype development \textit{in vitro} and \textit{in vivo}. Moreover, IL-6\textsuperscript{RFP} positive areas in tumor tissue revealed specific reduction of CSC markers including MSI-1 and Nanog, suggesting that STAT3 activity is directly associated with CSC marker expression. Recent studies imply the IL-6 cytokine to be essential to enter senescence (40, 41) and subsequently maintain de-differentiation/pluripotency (42). This is consistent with studies in glioblastoma showing that inhibition of the IL-6Ra expression diminished STAT3 activation, which was associated with reduced tumor growth and numbers of glioblastoma stem cells (7). Our data are consistent with and further expand on the studies of Wicha \textit{et al.} (43). Although previous studies have suggested that prostate CSCs are AR negative (44, 45), our findings indicate IL-6 secretion and downstream STAT3 mediated
signaling as a critical pathway after blockade of AR, thereby maintaining potential towards development of the CSC phenotype as well as initiating tumorigenic progression.

The efficacy of targeting CSCs is often hampered by drug resistance, which is a challenge for therapeutic intervention using small-molecule drugs that exert their inhibitory activity intracellularly. Previous studies have demonstrated elevated levels of proteins exerting multi-drug resistance such as ABCB1 and ABCG2 (46). Hence, inhibiting IL-6 with the IL-6RFP has several attractive aspects for targeting CSCs. Depletion of IL-6 is thought to impact the induction of cell senescence, which is considered one of the initial steps in the transition to a CSC phenotype (41). Blocking IL-6 would inhibit STAT3-mediated IL-6 signaling, which maintains the CSC phenotype, and downregulate STAT3 target gene induction such as Bcl-xL, Survivin, and c-Myc. Finally, IL-6 signaling repression is thought to negatively impact IL-6R-mediated MAPK signaling and PI3K signaling. The PI3K pathway is deregulated in many human tumors including prostate cancer and inhibition revealed promising results in cancer therapy (47). Therefore, our data suggest that IL-6RFP or similar strategies are promising therapeutic agents for PC to reduce tumor growth and prevent recurring PC by targeting the CSC population.

It is unlikely that mono-therapies targeting the IL-6/STAT3 signaling pathway will be effective for complete tumor rejection. It has been shown that first-line treatment inhibiting AR results in tumor regression, since the tumor bulk is eliminated. However, it seems possible that AR\textsuperscript{−}/pSTAT3\textsuperscript{+} expressing CSCs can survive and differentiate into AR-dependent tumor cells even with low levels of androgens. Thus, targeting the tumor bulk with an AR inhibitor and at the same time preventing the de-differentiated CSC cell population with high STAT3 activity is
likely advantageous. Combining inhibition of IL-6/STAT3 with androgen blockade resulted in improved therapeutic benefit compared to the respective mono-therapies. Importantly, IL-6 inhibition by IL-6RFP prevails over the anti-androgen induced CSC phenotype development. Hence, our data support the concept that combination of AR and STAT3 inhibitors may be the most effective PC therapy. A similar reciprocal regulation between AR and PI3K signaling has been found in Pten-deficient mice (48).

In summary, our results demonstrate that blockade of AR mediates activation of STAT3 signaling through up-regulation of IL-6, which is associated with the development of a CSC phenotype. Conversely, inhibition of the IL-6/STAT3 signaling pathway with IL-6 receptor fusion protein diminishes the CSC population, which results in reduced tumor growth. These findings provide new mechanistic insight into the emergence of drug resistant prostate cancer. Moreover, combination of IL-6RFP and anti-androgens inhibited CSCs and differentiated AR-positive cancer cells, and therefore provides a promising treatment of PC to prevent eventual tumor relapse.
Acknowledgments: We thank Dr. Cy Stein, Dr. Jeremy Jones, Dr. Tommy Tong and members of our laboratories for valuable comments and discussion. This work was supported by NCI grant R01 CA115674 (RJ) and by the Beckman Research Institute at City of Hope Comprehensive Cancer Center.

The authors declare that they have no conflict of interest.

Grant Support: Supported by NCI grant CA1155674 (to R.J.)


FIGURE LEGENDS

Figure 1. Downregulation of AR induces IL-6/STAT3 signaling.

(A) Rag1-/- mice with subcutaneous (s.c.) TC1 tumors were treated with 25 mg/kg flutamide or vehicle control intraperitoneally (i.p.), every other day, starting 28 d after engraftment (arrow). Mean tumor volume are shown (n=6-7). Tumors were harvested 2 hours after last treatment (V, F1, FII). (B) Activated and total STAT3 is upregulated in tumors treated with flutamide. Western blot analysis with antibodies as indicated. (C) Tumor sections were prepared for immunofluorescence staining. Shown are representative confocal microscopy images and mean fluorescence intensities (MFI), (n=3); green, pSTAT3 (upper row), or AR (lower row); blue, nuclear staining with Hoechst. Scale bar, 100 μm. (D) TC1 cells expressing AR_shRNA, STAT3_shRNA, or non-silencing control (ctrl) shRNA injected in NSG/NOD mice. Tumors were harvested 27 days upon tumor engraftment. Results are presented as mean tumor volume (n=6). (E) Representative results of western blot analysis for tyrosine-phosphorylated or total STAT3, STAT1, AR, GR, and β-Actin are shown. (A, C, D) Error bars represent standard deviation; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 2. Cancer Stem Cell phenotype development is mediated by Stat3 but not AR. (A) Frozen sections from TC1 tumor-bearing mice treated with vehicle control or flutamide were stained for MSI-1, Sox-2, or CD44, green. Shown are representative immunofluoresceces (left) and mean fluorescence intensities (MFI) of 3 different tumors (right). Hoechst was used for nuclear staining, blue. (B) Shown is a tumor sphere formation assay of TC1 cells expressing AR_shRNA, STAT3_shRNA or non-silencing control shRNA (n=7) (left). Western blot analysis with antibodies as indicated from TC1 tumor spheres (day 6) expressing AR_shRNA, STAT3_shRNA or
non-silencing control (right). (C) Immunofluorescence staining and mean fluorescence intensities (n=3) for MSI-1, and Sox2 of frozen tumor sections from mice injected with TC1 cells expressing AR$^{\text{shRNA}}$, STAT3$^{\text{shRNA}}$ or non-silencing control, nuclear staining: Hoechst. (D) Frozen sections of isolated TC1 tumors were stained for CD44 and AR or pSTAT3, Hoechst (blue). Double- and single-positive cells quantified (n=3). Scale bar: 100 µm. Standard deviation shown; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 3. Low AR and high STAT3 activity in human prostate cancer samples.

(A) Paraffin embedded slides of human PC tissue were stained for pSTAT3, and Sox2, or Integrin $\alpha_2\beta_1$; nuclear staining with Hoechst. Scale bar 100 µm, 10 µm in magnifications (left). Single-positive and double-positive cells quantified (right). (B) Immunofluorescence of human PC tissue stained for pSTAT3 and AR; Hoechst was added for nuclear staining (left). Intensity-coded wrong color mode of pSTAT3 and AR is depicted (right). (C) Shown is a representative image of a human prostate cancer section stained for AR and CD44, or Sox2. Hoechst was used for nuclear staining (left). Double- and single-positive cells quantified (n=3), (right). (D) Detailed analysis of Sox2 and AR, or pSTAT3 stained tumor sections. Fluorescence intensities of AR, Sox2 and pSTAT3 are depicted in an intensity-coded wrong color mode as indicated; nuclear staining with Hoechst (blue). Sale bars: 100 µm, 10 µm in magnifications. Standard deviation shown; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 4: Decreased CSC phenotype education upon IL-6$^{\text{RFP}}$ treatment.

(A) Tumor homogenates of mice treated with either vehicle control or flutamide (left) or homogenates from engineered TC1 tumor cells as indicated (right) were prepared for RT-PCR.
Bar graphs show fold inductions of IL-6 mRNA levels assessed in triplicate. (B) 30 days after tumor cell engraftment (arrow), TC1 tumor-bearing mice were treated with vehicle control (HEK\textsuperscript{CM}/IgG), 1.8 or 18 nM anti-IL-6 antibodies, or 1.8 nM IL-6\textsuperscript{RFP} twice daily. Mean tumor volumes shown (n=6). (C) Shown is a western blot from tumor homogenates of mice treated with vehicle or IL-6\textsuperscript{RFP}, detected with antibodies as indicated. (D) Immunofluorescences and MFIs (n=3) of tumor sections stained for pSTAT3 (red), His-tag (IL-6\textsuperscript{RFP}; green) and Hoechst (blue). (E) Immunofluorescent staining and MFIs for CD44 or Nanog (green), His-tag (IL-6\textsuperscript{RFP}; red); blue, Hoechst. MFIs of Nanog were measured in IL-6\textsuperscript{RFP} positive areas (n=3). (F) Tumor spheres of DU145 cells treated with vehicle or IL-6\textsuperscript{RFP} were quantified every other day (left). Spheres were imaged on day 6 (middle). Tumor spheres (day 6) were analyzed by western blot and detected with antibodies as indicated (right). (G) Tumor spheres of DU145 cells expressing STAT3\textsuperscript{shRNA} or non-silencing control shRNA were quantified every other day (left). Western blot analysis of tumorspheres with antibodies as indicated (right). (H) Nude mice with subcutaneous (s.c.) DU145 tumors were treated with 3.6 μg/kg IL-6\textsuperscript{RFP} or vehicle control peritumorally, starting 19 d after engraftment (arrow). Mean tumor volume shown (n=4). (I) Immunofluorescence staining of frozen tumor sections for pSTAT3, IL-6\textsuperscript{RFP} and Hoechst as indicated. (J) Fluorescence intensity profile of pSTAT3 (green) and IL-6\textsuperscript{RFP} (red) of IL-6\textsuperscript{RFP} treated mice from image shown in (I). (K) Tumors from mice treated with vehicle or IL-6\textsuperscript{RFP} were analyzed by western blot, detected with antibodies as indicated. Scale bars: 100 μm. Error bars represent standard deviation; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
**Figure 5: Impact of combined therapy using anti-androgen and IL-6RFP on tumor growth.**

(A) Mice with subcutaneous (s.c.) TC1 tumors treated with vehicle control, 50 mg/kg bicalutamide (i.p.), 3.6 μg/kg IL-6RFP (s.c.), or a combination of both. Injections of bicalutamide performed i.p. every other day. IL-6RFP administered s.c. daily. Mean tumor volumes shown (n=6). (B) Western blot analysis of tumor lysates with antibodies as indicated. (C) Shown are immunofluorescences and MFI s of frozen tumor tissue stained for Ki-67; nuclear staining with Hoechst. Scale bar: 100 μm. (D) IVMPM on TC1-tumors 2 h after treatment as indicated. Green, CD44-FITC; blue, ECM; Scale bar 200 μm. (E) Lysates from tumor tissue subjected to western blot and analyzed against pSTAT3, STAT3, MSI-1, Sox2, and GAPDH. Error bars represent standard deviation; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
**Figure 1.**

(A) Tumor volume growth curves for different treatments: Vehicle, Bicalutamide, IL-6RFP, and IL-6RFP/Bic.

(B) Western blot analysis of cytokine levels: Cleaved PARP, Cleaved Caspase3, Bcl-2, BclXL, and GAPDH.

(C) Immunohistochemistry for Ki-67 and Hoechst staining.

(D) Immunofluorescence for CD44 and ECM.

(E) Western blot analysis of signaling pathway markers: pSTAT3, STAT3, MSI-1, Sox2, and GAPDH.
Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling

Anne Schroeder, Andreas Herrmann, Gregory Cherryholmes, et al.

Cancer Res  Published OnlineFirst October 31, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-0594

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/10/31/0008-5472.CAN-13-0594.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.